WO2012065740A1 - Transdermal therapeutic system comprising buprenorphine - Google Patents
Transdermal therapeutic system comprising buprenorphine Download PDFInfo
- Publication number
- WO2012065740A1 WO2012065740A1 PCT/EP2011/005784 EP2011005784W WO2012065740A1 WO 2012065740 A1 WO2012065740 A1 WO 2012065740A1 EP 2011005784 W EP2011005784 W EP 2011005784W WO 2012065740 A1 WO2012065740 A1 WO 2012065740A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- acrylic polymer
- acid
- therapeutic system
- transdermal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK11784951.3T DK2640389T3 (en) | 2010-11-17 | 2011-11-17 | Transdermal therapeutic system comprising buprenorphine |
US13/885,958 US9844515B2 (en) | 2010-11-17 | 2011-11-17 | Transdermal therapeutic system comprising buprenorphine |
BR112013012156A BR112013012156A2 (pt) | 2010-11-17 | 2011-11-17 | sistema terapêutico transdérmico e método de produção de um sistema terapêutico transdérmico |
ES11784951.3T ES2528650T3 (es) | 2010-11-17 | 2011-11-17 | Sistema terapéutico transdérmico que comprende buprenorfina |
CN201180055476.XA CN103200944B (zh) | 2010-11-17 | 2011-11-17 | 包含丁丙诺啡的经皮治疗系统 |
AU2011331511A AU2011331511C1 (en) | 2010-11-17 | 2011-11-17 | Transdermal therapeutic system comprising buprenorphine |
CA2815898A CA2815898C (en) | 2010-11-17 | 2011-11-17 | Transdermal therapeutic system comprising buprenorphine |
EP11784951.3A EP2640389B1 (en) | 2010-11-17 | 2011-11-17 | Transdermal therapeutic system comprising buprenorphine |
US15/794,949 US20180042861A1 (en) | 2010-11-17 | 2017-10-26 | Transdermal therapeutic system comprising buprenorphrine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10014713 | 2010-11-17 | ||
EP10014713.1 | 2010-11-17 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/885,958 A-371-Of-International US9844515B2 (en) | 2010-11-17 | 2011-11-17 | Transdermal therapeutic system comprising buprenorphine |
US15/794,949 Division US20180042861A1 (en) | 2010-11-17 | 2017-10-26 | Transdermal therapeutic system comprising buprenorphrine |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012065740A1 true WO2012065740A1 (en) | 2012-05-24 |
Family
ID=43728780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/005784 WO2012065740A1 (en) | 2010-11-17 | 2011-11-17 | Transdermal therapeutic system comprising buprenorphine |
Country Status (9)
Country | Link |
---|---|
US (2) | US9844515B2 (zh) |
EP (1) | EP2640389B1 (zh) |
CN (1) | CN103200944B (zh) |
AU (1) | AU2011331511C1 (zh) |
BR (1) | BR112013012156A2 (zh) |
CA (1) | CA2815898C (zh) |
DK (1) | DK2640389T3 (zh) |
ES (1) | ES2528650T3 (zh) |
WO (1) | WO2012065740A1 (zh) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2305194B1 (en) | 1997-02-24 | 2012-05-09 | Euro-Celtique S.A. | A buprenorphine transdermal patch for use in the treatment of pain for a dosing interval of at least 7 days |
US20140178459A1 (en) * | 2012-12-21 | 2014-06-26 | Teikoku Pharma Usa, Inc. | Compositions and methods for transdermal delivery of hormones and other medicinal agents |
WO2014105480A1 (en) * | 2012-12-28 | 2014-07-03 | Teikoku Pharma Usa, Inc. | Extended buprenorphine transdermal delivery compositions and methods for using the same |
US8933059B2 (en) | 2012-06-18 | 2015-01-13 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8987237B2 (en) | 2011-11-23 | 2015-03-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150098983A1 (en) * | 2013-10-07 | 2015-04-09 | Teikoku Pharma Usa, Inc. | Methods and Compositions for Treating Withdrawal Syndromes Using Non-Sedative Dexmedetomidine Transdermal Compositions |
US20150098982A1 (en) * | 2013-10-07 | 2015-04-09 | Teikoku Pharma Usa, Inc. | Methods and Compositions for Managing Pain Comprising Dexmedetomidine Transdermal Compositions |
CN104736176A (zh) * | 2012-08-24 | 2015-06-24 | 英特格拉斯疗法有限公司 | 用于增强治疗剂透皮递送的化学组合物和方法 |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US20160022627A2 (en) * | 2014-04-18 | 2016-01-28 | Mary's Medicinals LLC | Transdermal cannabinoid patch |
KR20160014064A (ko) * | 2013-06-04 | 2016-02-05 | 에르테에스 로만 테라피-시스테메 아게 | 경피 전달 시스템 |
DE102014013448A1 (de) | 2014-09-16 | 2016-03-17 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales Therapeutisches System umfassend Buprenorphin |
US9289382B2 (en) | 2012-06-18 | 2016-03-22 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
EP3067050A1 (en) * | 2015-03-13 | 2016-09-14 | Acino AG | Transdermal therapeutic system with an overtape comprising two adhesive layers |
US9656441B2 (en) | 2015-01-08 | 2017-05-23 | Alfred E. Tiefenbacher ( Gmbh & Co. Kg) | Transdermal patch |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10052386B2 (en) | 2012-06-18 | 2018-08-21 | Therapeuticsmd, Inc. | Progesterone formulations |
EP3412283A1 (de) * | 2017-06-07 | 2018-12-12 | AMW GmbH | Overtape für ein transdermales darreichungssystem |
US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10258630B2 (en) | 2014-10-22 | 2019-04-16 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
WO2019175096A1 (en) * | 2018-03-13 | 2019-09-19 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for the transdermal administration of buprenorphine comprising a silicone acrylic hybrid polymer |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471148B2 (en) | 2012-06-18 | 2019-11-12 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable PK profile |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10772871B2 (en) | 2013-10-07 | 2020-09-15 | Teikoku Pharma Usa, Inc. | Dexmedetomidine transdermal delivery devices and methods for using the same |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10874642B2 (en) | 2013-10-07 | 2020-12-29 | Teikoku Pharma Usa, Inc. | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions |
WO2021007584A1 (en) * | 2019-07-11 | 2021-01-14 | Henkel IP & Holding GmbH | Acrylic polymer and adhesive compositions |
US10987342B2 (en) | 2013-10-07 | 2021-04-27 | Teikoku Pharma Usa, Inc. | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
WO2008153611A2 (en) | 2007-05-25 | 2008-12-18 | Qlt Usa, Inc. | Sustained delivery formulations of risperidone compounds |
GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
WO2015006528A1 (en) * | 2013-07-10 | 2015-01-15 | Jie Zhang | A kit for sustained transdermal drug delivery using liquid or semisolid formulations and method of using the same |
GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
AR098771A1 (es) * | 2014-12-16 | 2016-06-15 | Amarin Tech S A | Un dispositivo para la administración transdérmica de rotigotina |
US20180256562A1 (en) * | 2015-09-14 | 2018-09-13 | Amneal Pharmaceuticals Llc | Transdermal Delivery System |
AR102214A1 (es) * | 2015-10-08 | 2017-02-15 | Amarin Tech S A | Un dispositivo para la administración transdermal de buprenorfina |
US10716754B2 (en) | 2016-03-28 | 2020-07-21 | Tioga Research, Inc. | Topical formulation |
US11541018B2 (en) | 2016-06-23 | 2023-01-03 | Corium, Llc | Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent |
CA3031945A1 (en) | 2016-07-27 | 2018-02-01 | Corium International, Inc. | Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs by in situ salt-to-neutral drug conversion of salt drug |
WO2018115001A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
WO2018115010A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
ES2881783T3 (es) | 2017-06-26 | 2021-11-30 | Lts Lohmann Therapie Systeme Ag | Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona |
CA3086163A1 (en) | 2017-12-20 | 2019-06-27 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
KR102255560B1 (ko) | 2018-02-20 | 2021-05-24 | 주식회사 엘지화학 | 점착제 조성물 및 이를 포함하는 점착 필름 |
MX2020014286A (es) | 2018-06-20 | 2021-03-25 | Lts Lohmann Therapie Systeme Ag | Sistema terapeutico transdermico que contiene asenapina. |
US20210275467A1 (en) * | 2018-07-09 | 2021-09-09 | Tyme, Inc | Tumor reduction formulations and methods of use thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0430019A2 (de) * | 1989-11-29 | 1991-06-05 | LTS Lohmann Therapie-Systeme GmbH & Co. KG | Transdermales therapeutisches System mit Buprenorphin als aktivem Bestandteil |
EP0819438A2 (en) | 1996-07-19 | 1998-01-21 | Nitto Denko Corporation | Buprenorphine percutaneous absorption preparation |
EP0792145B1 (de) | 1994-12-24 | 1998-10-28 | LTS LOHMANN Therapie-Systeme GmbH | Transdermale resorption von wirkstoffen aus unterkühlten schmelzen |
US6231886B1 (en) * | 1997-02-24 | 2001-05-15 | Robert F. Reder | Methods of providing sustained treatment with opioids |
US6344211B1 (en) * | 1994-12-24 | 2002-02-05 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal absorption of active substances from subcooled melts |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5240711A (en) * | 1989-11-29 | 1993-08-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system comprising as active component buprenorphine |
DE4301783C1 (de) | 1993-01-23 | 1994-02-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil |
DK0695177T3 (da) | 1993-04-20 | 1998-09-28 | Hexal Ag | Plaster indeholdende aktivt stof |
PT1718258E (pt) | 2004-02-23 | 2009-06-16 | Euro Celtique Sa | Dispositivo de administração transdérmica de opióides com resistência ao abuso |
DE102004020463A1 (de) | 2004-04-26 | 2005-11-10 | Grünenthal GmbH | Wirkstoffabgabesystem aus einem wirkstoffhaltigen Pflaster und mindestens einem Wirkstoffabgaberegulierungsmittel |
-
2011
- 2011-11-17 DK DK11784951.3T patent/DK2640389T3/en active
- 2011-11-17 CA CA2815898A patent/CA2815898C/en active Active
- 2011-11-17 EP EP11784951.3A patent/EP2640389B1/en not_active Not-in-force
- 2011-11-17 WO PCT/EP2011/005784 patent/WO2012065740A1/en active Application Filing
- 2011-11-17 BR BR112013012156A patent/BR112013012156A2/pt not_active Application Discontinuation
- 2011-11-17 CN CN201180055476.XA patent/CN103200944B/zh not_active Expired - Fee Related
- 2011-11-17 US US13/885,958 patent/US9844515B2/en active Active
- 2011-11-17 AU AU2011331511A patent/AU2011331511C1/en not_active Ceased
- 2011-11-17 ES ES11784951.3T patent/ES2528650T3/es active Active
-
2017
- 2017-10-26 US US15/794,949 patent/US20180042861A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0430019A2 (de) * | 1989-11-29 | 1991-06-05 | LTS Lohmann Therapie-Systeme GmbH & Co. KG | Transdermales therapeutisches System mit Buprenorphin als aktivem Bestandteil |
EP0430019B1 (de) | 1989-11-29 | 1996-03-13 | LTS Lohmann Therapie-Systeme GmbH & Co. KG | Transdermales therapeutisches System mit Buprenorphin als aktivem Bestandteil |
EP0792145B1 (de) | 1994-12-24 | 1998-10-28 | LTS LOHMANN Therapie-Systeme GmbH | Transdermale resorption von wirkstoffen aus unterkühlten schmelzen |
US6344211B1 (en) * | 1994-12-24 | 2002-02-05 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal absorption of active substances from subcooled melts |
EP0819438A2 (en) | 1996-07-19 | 1998-01-21 | Nitto Denko Corporation | Buprenorphine percutaneous absorption preparation |
US6231886B1 (en) * | 1997-02-24 | 2001-05-15 | Robert F. Reder | Methods of providing sustained treatment with opioids |
Non-Patent Citations (1)
Title |
---|
"ECD Guidelines for the Testing of Chemicals/Section 4: Health Effects", 2004, OECD PUBLISHING |
Cited By (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1731152B1 (en) | 1997-02-24 | 2013-05-01 | Euro-Celtique S.A. | Sustained analgesia achieved with transdermal delivery of buprenorphine |
EP2305194B1 (en) | 1997-02-24 | 2012-05-09 | Euro-Celtique S.A. | A buprenorphine transdermal patch for use in the treatment of pain for a dosing interval of at least 7 days |
US9114145B2 (en) | 2011-11-23 | 2015-08-25 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10675288B2 (en) | 2011-11-23 | 2020-06-09 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11103516B2 (en) | 2011-11-23 | 2021-08-31 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9248136B2 (en) | 2011-11-23 | 2016-02-02 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US8987237B2 (en) | 2011-11-23 | 2015-03-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8993549B2 (en) | 2011-11-23 | 2015-03-31 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8993548B2 (en) | 2011-11-23 | 2015-03-31 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9114146B2 (en) | 2011-11-23 | 2015-08-25 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11793819B2 (en) | 2011-11-23 | 2023-10-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8933059B2 (en) | 2012-06-18 | 2015-01-13 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11166963B2 (en) | 2012-06-18 | 2021-11-09 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9006222B2 (en) | 2012-06-18 | 2015-04-14 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11865179B2 (en) | 2012-06-18 | 2024-01-09 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable PK profile |
US10639375B2 (en) | 2012-06-18 | 2020-05-05 | Therapeuticsmd, Inc. | Progesterone formulations |
US10471148B2 (en) | 2012-06-18 | 2019-11-12 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable PK profile |
US11033626B2 (en) | 2012-06-18 | 2021-06-15 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US8987238B2 (en) | 2012-06-18 | 2015-03-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10052386B2 (en) | 2012-06-18 | 2018-08-21 | Therapeuticsmd, Inc. | Progesterone formulations |
US9012434B2 (en) | 2012-06-18 | 2015-04-21 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11529360B2 (en) | 2012-06-18 | 2022-12-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9289382B2 (en) | 2012-06-18 | 2016-03-22 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11110099B2 (en) | 2012-06-18 | 2021-09-07 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
CN107582544A (zh) * | 2012-08-24 | 2018-01-16 | 英特格拉斯疗法有限公司 | 用于增强治疗剂透皮递送的化学组合物和方法 |
CN104736176A (zh) * | 2012-08-24 | 2015-06-24 | 英特格拉斯疗法有限公司 | 用于增强治疗剂透皮递送的化学组合物和方法 |
US11065197B2 (en) | 2012-12-21 | 2021-07-20 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10835487B2 (en) | 2012-12-21 | 2020-11-17 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11241445B2 (en) | 2012-12-21 | 2022-02-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11304959B2 (en) | 2012-12-21 | 2022-04-19 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11351182B2 (en) | 2012-12-21 | 2022-06-07 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11123283B2 (en) | 2012-12-21 | 2021-09-21 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11116717B2 (en) | 2012-12-21 | 2021-09-14 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11497709B2 (en) | 2012-12-21 | 2022-11-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20140178459A1 (en) * | 2012-12-21 | 2014-06-26 | Teikoku Pharma Usa, Inc. | Compositions and methods for transdermal delivery of hormones and other medicinal agents |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11622933B2 (en) | 2012-12-21 | 2023-04-11 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10888516B2 (en) | 2012-12-21 | 2021-01-12 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US9579296B2 (en) | 2012-12-21 | 2017-02-28 | Teikoku Pharma Usa, Inc. | Compositions and methods for transdermal delivery of hormones and other medicinal agents |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9144553B2 (en) | 2012-12-21 | 2015-09-29 | Teikoku Pharma Usa, Inc. | Compositions and methods for transdermal delivery of hormones and other medicinal agents |
US11547676B2 (en) | 2012-12-28 | 2023-01-10 | Teikoku Seiyaku Co., Ltd. | Extended buprenorphine transdermal delivery compositions and methods for using the same |
WO2014105480A1 (en) * | 2012-12-28 | 2014-07-03 | Teikoku Pharma Usa, Inc. | Extended buprenorphine transdermal delivery compositions and methods for using the same |
KR20160014064A (ko) * | 2013-06-04 | 2016-02-05 | 에르테에스 로만 테라피-시스테메 아게 | 경피 전달 시스템 |
CN105377245A (zh) * | 2013-06-04 | 2016-03-02 | Lts勒曼治疗系统股份公司 | 透皮递送系统 |
US11529345B2 (en) | 2013-06-04 | 2022-12-20 | Lts Lohmann Therapie-Systeme Ag | Buprenorphine transdermal delivery system |
JP2016520638A (ja) * | 2013-06-04 | 2016-07-14 | エルテーエス ローマン テラピー−ジステーメ アーゲー | 経皮送達システム |
EP3106153A1 (en) * | 2013-06-04 | 2016-12-21 | LTS LOHMANN Therapie-Systeme AG | Transdermal delivery system |
CN105377245B (zh) * | 2013-06-04 | 2018-07-17 | Lts勒曼治疗系统股份公司 | 透皮递送系统 |
KR102302505B1 (ko) * | 2013-06-04 | 2021-09-15 | 에르테에스 로만 테라피-시스테메 아게 | 경피 전달 시스템 |
US10772871B2 (en) | 2013-10-07 | 2020-09-15 | Teikoku Pharma Usa, Inc. | Dexmedetomidine transdermal delivery devices and methods for using the same |
US20150098983A1 (en) * | 2013-10-07 | 2015-04-09 | Teikoku Pharma Usa, Inc. | Methods and Compositions for Treating Withdrawal Syndromes Using Non-Sedative Dexmedetomidine Transdermal Compositions |
US20150098982A1 (en) * | 2013-10-07 | 2015-04-09 | Teikoku Pharma Usa, Inc. | Methods and Compositions for Managing Pain Comprising Dexmedetomidine Transdermal Compositions |
US10874642B2 (en) | 2013-10-07 | 2020-12-29 | Teikoku Pharma Usa, Inc. | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions |
US10987342B2 (en) | 2013-10-07 | 2021-04-27 | Teikoku Pharma Usa, Inc. | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine |
US20160022627A2 (en) * | 2014-04-18 | 2016-01-28 | Mary's Medicinals LLC | Transdermal cannabinoid patch |
US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11103513B2 (en) | 2014-05-22 | 2021-08-31 | TherapeuticsMD | Natural combination hormone replacement formulations and therapies |
DE102014013448A1 (de) | 2014-09-16 | 2016-03-17 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales Therapeutisches System umfassend Buprenorphin |
US10668082B2 (en) | 2014-10-22 | 2020-06-02 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10258630B2 (en) | 2014-10-22 | 2019-04-16 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10398708B2 (en) | 2014-10-22 | 2019-09-03 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9656441B2 (en) | 2015-01-08 | 2017-05-23 | Alfred E. Tiefenbacher ( Gmbh & Co. Kg) | Transdermal patch |
WO2016146585A1 (en) * | 2015-03-13 | 2016-09-22 | Acino Ag | Transdermal therapeutic system with an overtape comprising two adhesive layers |
EP3067050A1 (en) * | 2015-03-13 | 2016-09-14 | Acino AG | Transdermal therapeutic system with an overtape comprising two adhesive layers |
US11013697B2 (en) | 2015-03-13 | 2021-05-25 | Luye Pharma Ag | Transdermal therapeutic system with an overtape comprising two adhesive layers |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10912783B2 (en) | 2015-07-23 | 2021-02-09 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10532059B2 (en) | 2016-04-01 | 2020-01-14 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
EP3412283A1 (de) * | 2017-06-07 | 2018-12-12 | AMW GmbH | Overtape für ein transdermales darreichungssystem |
WO2019175096A1 (en) * | 2018-03-13 | 2019-09-19 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for the transdermal administration of buprenorphine comprising a silicone acrylic hybrid polymer |
WO2021007584A1 (en) * | 2019-07-11 | 2021-01-14 | Henkel IP & Holding GmbH | Acrylic polymer and adhesive compositions |
Also Published As
Publication number | Publication date |
---|---|
AU2011331511B2 (en) | 2016-04-07 |
US20180042861A1 (en) | 2018-02-15 |
EP2640389B1 (en) | 2014-12-31 |
CN103200944B (zh) | 2016-05-04 |
CN103200944A (zh) | 2013-07-10 |
AU2011331511C1 (en) | 2018-01-18 |
CA2815898C (en) | 2018-12-18 |
US9844515B2 (en) | 2017-12-19 |
DK2640389T3 (en) | 2015-03-09 |
US20130331803A1 (en) | 2013-12-12 |
AU2011331511A1 (en) | 2013-05-30 |
BR112013012156A2 (pt) | 2017-12-05 |
CA2815898A1 (en) | 2012-05-24 |
EP2640389A1 (en) | 2013-09-25 |
ES2528650T3 (es) | 2015-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180042861A1 (en) | Transdermal therapeutic system comprising buprenorphrine | |
CN100340237C (zh) | 吸水性和粘附性能改善的经皮给药系统 | |
ES2762460T3 (es) | Composiciones y métodos de administración dérmica | |
US7501358B2 (en) | Adhesive preparation | |
JP2015108007A (ja) | 中和されたアクリル性粘着パッチを備えた経皮治療システム | |
US20060193900A1 (en) | Pressure sensitive adhesive and patch | |
JPWO2005115355A1 (ja) | 貼付製剤 | |
WO2009139411A1 (ja) | パロノセトロンを含有する経皮吸収製剤 | |
JP2011252003A (ja) | 気管支拡張剤ツロブテロールを皮膚から投与するための塩酸ツロブテロールを含む経皮治療システム | |
US20180256562A1 (en) | Transdermal Delivery System | |
AU4802599A (en) | Pressure-sensitive adhesive composition and moisture-permeable pressure-sensitive adhesive tape, pressure-sensitive adhesive drug composition, and pressure-sensitive adhesive tape preparation each containing the composition | |
CN1678352A (zh) | 贴剂 | |
WO2008026381A1 (en) | Nail patch | |
CA3162229A1 (en) | Transdermal therapeutic system containing agomelatine | |
KR101842315B1 (ko) | 첩부 제제 | |
EP2601944B1 (en) | Transdermal patch and method for augmenting adhesive strength thereof | |
US8968774B2 (en) | Preparation and composition of meloxicam transdermal drug delivery system | |
JP6773897B2 (ja) | 貼付剤 | |
JP6512905B2 (ja) | フェンタニル含有貼付剤 | |
JP6864968B2 (ja) | 貼付剤 | |
KR20220158748A (ko) | 첩부제 | |
TW202135830A (zh) | 貼附劑 | |
EP2462927A1 (en) | Transdermal therapeutic system comprising fentanyl |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180055476.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11784951 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2815898 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011331511 Country of ref document: AU Date of ref document: 20111117 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13885958 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011784951 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013012156 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013012156 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130516 |